Ardsley Advisory Partners Invests $415,000 in Voyager Therapeutics Inc (VYGR) Stock

Ardsley Advisory Partners acquired a new stake in Voyager Therapeutics Inc (NASDAQ:VYGR) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 25,000 shares of the company’s stock, valued at approximately $415,000.

A number of other hedge funds have also made changes to their positions in VYGR. Thompson Davis & CO. Inc. boosted its stake in Voyager Therapeutics by 67.7% in the fourth quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock valued at $124,000 after acquiring an additional 3,021 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after acquiring an additional 1,399 shares during the last quarter. Teachers Advisors LLC boosted its stake in Voyager Therapeutics by 24.7% in the second quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after acquiring an additional 5,081 shares during the last quarter. California State Teachers Retirement System boosted its stake in Voyager Therapeutics by 8.4% in the second quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Bailard Inc. bought a new position in Voyager Therapeutics in the fourth quarter valued at approximately $232,000. 80.03% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

In other news, insider Bernard Ravina sold 3,630 shares of Voyager Therapeutics stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $16.40, for a total transaction of $59,532.00. Following the transaction, the insider now directly owns 7,353 shares of the company’s stock, valued at $120,589.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Dinah Ph.D. Sah sold 15,623 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total transaction of $468,690.00. Following the transaction, the insider now directly owns 140,872 shares in the company, valued at $4,226,160. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,704 shares of company stock worth $572,928. Insiders own 8.00% of the company’s stock.

Voyager Therapeutics Inc (VYGR) opened at $24.28 on Tuesday. The firm has a market cap of $724.67 and a price-to-earnings ratio of -8.55. Voyager Therapeutics Inc has a 52-week low of $8.10 and a 52-week high of $31.91.

VYGR has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Morgan Stanley initiated coverage on shares of Voyager Therapeutics in a research note on Friday, February 2nd. They issued an “overweight” rating on the stock. BidaskClub raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, February 24th. Piper Jaffray Companies set a $40.00 price target on shares of Voyager Therapeutics and gave the stock a “buy” rating in a research report on Monday. Finally, BTIG Research reissued a “buy” rating and set a $32.00 price target on shares of Voyager Therapeutics in a research report on Sunday. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. Voyager Therapeutics has an average rating of “Buy” and an average target price of $29.20.

WARNING: “Ardsley Advisory Partners Invests $415,000 in Voyager Therapeutics Inc (VYGR) Stock” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.themarketsdaily.com/2018/03/13/ardsley-advisory-partners-invests-415000-in-voyager-therapeutics-inc-vygr-stock.html.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply